Evaluation of rMETase-Loaded Stealth PLGA/Liposomes Modified with Anti-CAGE scFV for Treatment of Gastric Carcinoma.
Stealth PLGA/Liposome nanoparticles (NPs) modified with tumor-targeting single-chain antibody fragment (scFV-P/L) for systemic delivery of recombinant methioninase (rMETase) for gastric cancer were prepared. The morphologies and therapeutic effects of rMETase-loaded scFV-P/L (scFV-rMETase-P/L) in vitro were analyzed. Functional scFV-P/L NPs composed of PLGA, DOPC and DSPE-PEG display low cell cytoxicity in SGC-7901 cells, and has more cell uptake ability than P/L NPs. scFV-rMETase-P/L was more effective in inhibiting tumor growth in the subcutaneous gastric carcinoma tumor model than free rMETase in solution (p < 0.05) and rMETase-loaded P/L (rMETase-P/L) (p < 0.05). Our findings collectively support the utility of scFV-targeted P/L NPs as a potentially effective drug delivery system.